Sekisui Chemical Company has acquired Genzyme Corporation’s Diagnostic Product Division
Lincoln International, a leading global mid-market investment bank, has announced that Sekisui Chemical Company, the Tokyo stock exchange-listed manufacturer of a broad range of products in Japan and internationally, has completed its acquisition of Genzyme Corporation’s Diagnostic Products division for $265 million in cash.
Genzyme Diagnostics is a leading provider of global diagnostic products for diagnostics manufacturers, clinical laboratories and physician offices. Sekisui acquired facilities in the U.S., Canada, Germany and the U.K. and is retaining approximately 575 employees.
Lincoln International acted as the exclusive financial advisor to Sekisui, working closely with the senior management team throughout the sale process. This included providing advisory expertise and managing the negotiation and due diligence phases of the transaction.
Meet our Senior Team
View More Transactions
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.